Topic Hub
5 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Explore
Showing 5 of 5 clinical reviews.
Evidence-based guide to low-dose naltrexone (LDN) dosing, pharmacogenomics, and clinical considerations specific to Black and African ancestry patients, reviewed by the HealthRX.com medical team.
Read clinical reviewEvidence-based guide to Low-Dose Naltrexone (LDN) dosing in Hispanic and Latino patients, covering CYP2D6 pharmacogenomics, metabolic considerations, and clinical monitoring protocols.
Read clinical reviewA detailed clinical review of pharmacogenomic and pharmacokinetic factors that may explain efficacy differences with low-dose naltrexone (LDN) in East Asian patients, including CYP2D6/CYP2C19 polymorphisms, dosing guidance, and what the current evidence actually shows.
Read clinical reviewEast Asian patients metabolize naltrexone differently due to CYP2D6 and OPRM1 A118G variant frequencies. Learn how to adjust low-dose naltrexone (LDN) dosing, what the pharmacogenomic evidence says, and what clinicians should monitor.
Read clinical reviewA clinical deep-dive into how ancestry-related pharmacogenomics, opioid receptor variants, and trial enrollment gaps affect low-dose naltrexone outcomes in Black and African ancestry patients.
Read clinical review